Company / Shareholders' Equity
Barinthus Biotherapeutics plc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$74.2M
FY2025
5-year range
-$36.9M / $242.9M
FY2021-FY2025
Trend
-42.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $243M in FY2022 to $74M in FY2025.
Based on SEC 10-K filings.
$74M in FY2025 with a 3-year CAGR of -32.6%.
Declined from $187M to $74M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -32.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Barinthus Biotherapeutics plc.'s shareholders' equity has declined for 3 consecutive years.
- 3-year CAGR of -32.6%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 42.9% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.2M | -42.9% |
| FY2024 | $130.0M | -30.4% |
| FY2023 | $186.8M | -23.1% |
| FY2022 | $242.9M | +758.0% |
| FY2021 | -$36.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026